

# Eye on Equity

## A Comprehensive Approach to DR/DME Care in Underrepresented Populations

### Activity Description

Nearly 30% of patients with diabetes in the United States aged  $\geq 40$  years are affected by diabetic retinopathy (DR) and diabetic macular edema (DME), and the prevalence is continuing to grow alongside the diabetes epidemic. Underserved populations, especially racial and ethnic minorities, are impacted at a higher rate and experience worsened progression due to ongoing healthcare disparities and barriers to care. Fortunately, opportunities to close these care gaps and improve outcomes abound! This new live event from PeerView will explore strategies to provide an early diagnosis, updates on the latest evidence for treatment, and best practices in recognizing and addressing disparities in the management of DR/DME. Join us, and discover how to keep an eye on equity!

### Target Audience

This activity has been designed to meet the educational needs of ophthalmologists, optometrists, and other healthcare professionals involved in the care of patients with diabetic retinopathy and diabetic macular edema.

### Educational Objectives

Upon completion of this activity, participants should be better able to:

- Summarize the unmet clinical needs and barriers to timely identification of DR/DME, including among people of color and other underserved populations
- Apply multidisciplinary care strategies that address barriers to timely DR/DME care and facilitate early referral to retina specialists
- Integrate clinical trial and real-world data into individualized treatment plans for diverse patient populations with DME
- Identify team-based communication and other strategies to facilitate adherence to recommended DME treatment protocols across different patient demographics

### Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will

receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

### Accreditation, Support, and Credit



In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

### Physicians

PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### COPE Statement



PVI, PeerView Institute for Medical Education, designates this synchronous activity for a maximum of 1.0 COPE credit hours. Course number: 97600-TD. Activity number: 130610.

### Interprofessional Continuing Education (IPCE) Statement



This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

### Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or

# PeerView

Live

This CME/COPE/IPCE activity is provided by PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

## PeerView.com/DR-DME-Survey-SYS



# Eye on Equity

## A Comprehensive Approach to DR/DME Care in Underrepresented Populations

distributes healthcare goods or services consumed by or used on patients.

**All relevant conflicts of interest have been mitigated prior to the commencement of the activity.**

### Chair/Planner

Joseph M. Coney, MD, FACS, FASRS  
Retina Associates of Cleveland, Inc.  
Beachwood, Ohio

Joseph M. Coney, MD, FACS, FASRS, has a financial interest/relationship or affiliation in the form of:

*Consultant and/or Advisor* for AbbVie Inc./Allergan; Alimera Sciences/ANI Pharmaceuticals; Apellis Pharmaceuticals; Bausch + Lomb Corporation; Coherus BioSciences; Genentech, Inc./F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.  
*Grant/Research Support* from 4D Molecular Therapeutics; AbbVie Inc./Allergan; Alimera Sciences/ANI Pharmaceuticals; Apellis Pharmaceuticals; Aviceda Therapeutics; Eyebio Limited; Genentech, Inc./F. Hoffmann-La Roche Ltd; National Eye Institute; Neurotech Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; MacTel; Regeneron Pharmaceuticals Inc.; and REGENXBIO Inc.

*Speaker* for AbbVie Inc./Allergan; Alimera Sciences/ANI Pharmaceuticals; Apellis Pharmaceuticals; Genentech, Inc./F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals Inc.

*Speakers Bureau* participant with Astellas Pharma US, Inc./Iveric Bio.

### Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

### Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### About This CME/COPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

PeerView  
Live

This CME/COPE/IPCE activity is provided by PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

[PeerView.com/DR-DME-Survey-SYS](https://www.peerview.com/DR-DME-Survey-SYS)

